Audio

Anthony Reder, MD, Discusses a 21-Year Follow-Up Study of Patients Who Have Multiple Sclerosis

Neurology Reviews. 2012 July;20(7)

 

To read an accompanying article, please click here.

Recommended Reading

CombiRx for MS Not Better Than Monotherapy
MDedge Neurology
Interferon-Beta Fails to Slow the Progression of Disability in MS
MDedge Neurology
FDA Reports Seizure Risk With MS Drug
MDedge Neurology
MS Use Leads to Free Campath for Leukemia Patients
MDedge Neurology
Will They Still Give Strong to Lance Armstrong's Cancer Charity?
MDedge Neurology
New and Noteworthy Information—August
MDedge Neurology
Long-Term Data Indicate Interferon Beta-1b Reduces the Risk of Death for Patients With MS
MDedge Neurology
Interferon Beta May Not Reduce Disability Progression for Patients With MS
MDedge Neurology
Should Patients Continue Natalizumab Treatment After a Positive JCV Test?
MDedge Neurology
Cognitive Rehabilitation Improves Quality of Life in Patients With MS
MDedge Neurology